Instruction for use: Dalfaz

Trade name of the drug – Dalfaz

Dosage Form: tablets

Composition (per tablet): coated tablets - alfuzosin (as hydrochloride) 2,5 mg; in blister 15 pcs .; In the paper cartons 2 blisters.

Pharmacotherapeutic group: Alpha- and beta-blockers

The nosological classification (ICD-10)

N40 Hyperplasia of prostate gland: Prostate adenoma; BPH; Prostatauxe; prostate Hypertrophy; Dysuric disorders caused by benign prostatic hyperplasia; Dizuricheskie disorder with benign prostatic hyperplasia; Dysuria with prostate cancer; Benign prostatic giperpalaziya; Benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2; Benign prostatic hyperplasia I degree; Benign prostatic hyperplasia II degree; Benign prostatic hypertrophy; The disease of the prostate gland; Acute urinary retention related to benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2 in combination with prostatitis; paradoxical ischuria

Pharmacological Properties of Dalfaz

Pharmachologic effect - Mode of action – alpha adrenoliticheskoe.

The selective alpha-blocker. Blocks predominantly alpha 1-adrenoceptors in the prostate area, urethra and bladder triangle corrects urodynamics.

Pharmacodynamics

It lowers pressure in the urethra and reduce the resistance to current urine; It facilitates urination and eliminates dysuria. At therapeutic doses it has no effect on alpha1-adrenergic receptors of the vascular wall.

Pharmacokinetics

After oral doses of 5 mg Cmax achieved after 3 hours Plasma protein binding -. 90%, T1 / 2 - 8 h Mostly metabolized.. Write mainly in the bile and faeces in the form of inactive metabolites. In elderly people the absorption takes place more rapidly, the Cmax and bioavailability - higher volume of distribution - below, T1 / 2 remains unchanged. In patients with renal insufficiency, volume of distribution and total Cl increased by reducing the degree of binding to plasma proteins. Even with severe renal failure (Cl creatinine - 15-40 ml / min), there is no accumulation (high degree of biotransformation). In chronic heart failure the pharmacokinetic parameters do not change.

Indications for Dalfaz

Functional disorders of urination in benign prostatic hyperplasia.

Contraindications for Dalfaz

Hypersensitivity, orthostatic hypotension, a history of severe impairment of liver function, concomitant use of other alpha-blockers.

Dalfaz Dosage and Administration

The inside is not liquid, 5 mg in the morning and evening (daily dose 10 mg); begin treatment with an evening reception. Elderly and patients receiving antihypertensive therapy - 5 mg / day in the evening, if necessary, increase the dose - 10 mg / day (no more).

Side effect of Dalfaz

Most often - nausea, diarrhea, gastralgia, headache, dizziness, weakness. Less often - orthostatic hypotension, edema, somnolence, asthenia, tachycardia, dry mouth, skin redness, skin rash, pruritus. Sometimes - worsening angina (patients with IHD).

Interaction

Incompatible with others. Alpha1-blockers. It enhances the effects of antihypertensive drugs and general anesthetics.

Precautions for use Dalfaz

Be wary appoint patients with ischemic heart disease, renal failure, hypertensive patients taking antihypertensives.

Storage conditions of Dalfaz

In a dry, dark place at a temperature no higher than 25 ° C.

Keep out of the reach of children.

Shelf life

3 years.

Do not use beyond the expiration date printed on the package.

Conditions of supply of pharmacies

On prescription.